DK1169021T3 - Sammensætninger og fremgangsmåder til behandling af lymfom - Google Patents

Sammensætninger og fremgangsmåder til behandling af lymfom

Info

Publication number: DK1169021T3
Authority: DK; Denmark
Prior art keywords: mol; compositions; methods; cholesterol; lymphoma
Prior art date: 1999-04-01

Application number

DK00920004T

Other languages

Danish (da)

English (en)

Inventor

D Lawrence Mayer

Murray S Webb

Clive T R Burge

Andreas H Sarris

Patricia M Logan

Fernando Cabanillas

James H Goldie

Original Assignee

Hana Biosciences Inc

Univ Texas

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-04-01

Filing date

2000-03-31

Publication date

2010-01-11

2000-03-31 Application filed by Hana Biosciences Inc, Univ Texas filed Critical Hana Biosciences Inc

2010-01-11 Application granted granted Critical

2010-01-11 Publication of DK1169021T3 publication Critical patent/DK1169021T3/da

Links

206010025323 Lymphomas Diseases 0.000 title abstract 2
239000000203 mixture Substances 0.000 title 1
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 6
235000012000 cholesterol Nutrition 0.000 abstract 3
OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 abstract 2
229960004528 vincristine Drugs 0.000 abstract 2
OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 abstract 2
208000024893 Acute lymphoblastic leukemia Diseases 0.000 abstract 1
208000014697 Acute lymphocytic leukaemia Diseases 0.000 abstract 1
206010028980 Neoplasm Diseases 0.000 abstract 1
208000015914 Non-Hodgkin lymphomas Diseases 0.000 abstract 1
206010035226 Plasma cell myeloma Diseases 0.000 abstract 1
201000011510 cancer Diseases 0.000 abstract 1
208000032839 leukemia Diseases 0.000 abstract 1
239000002502 liposome Substances 0.000 abstract 1
201000000050 myeloid neoplasm Diseases 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/475—Quinolines; Isoquinolines having an indole ring, e.g. yohimbine, reserpine, strychnine, vinblastine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers
- A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes or liposomes coated or grafted with polymers comprising non-phosphatidyl surfactants as bilayer-forming substances, e.g. cationic lipids or non-phosphatidyl liposomes coated or grafted with polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Epidemiology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Bioinformatics & Cheminformatics (AREA)
Physical Education & Sports Medicine (AREA)
Engineering & Computer Science (AREA)
Hematology (AREA)
Dispersion Chemistry (AREA)
Oncology (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Saccharide Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

DK00920004T 1999-04-01 2000-03-31 Sammensætninger og fremgangsmåder til behandling af lymfom DK1169021T3 (da)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US12744499P	1999-04-01	1999-04-01
US13719499P	1999-06-02	1999-06-02
PCT/US2000/008669 WO2000059473A1 (en)	1999-04-01	2000-03-31	Compositions and methods for treating lymphoma

Publications (1)

Publication Number	Publication Date
DK1169021T3 true DK1169021T3 (da)	2010-01-11

Family

ID=26825635

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
DK10011105.3T DK2266537T3 (en)	1999-04-01	2000-03-31	Compositions for treating cancer
DK00920004T DK1169021T3 (da)	1999-04-01	2000-03-31	Sammensætninger og fremgangsmåder til behandling af lymfom

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
DK10011105.3T DK2266537T3 (en)	1999-04-01	2000-03-31	Compositions for treating cancer

Country Status (13)

Country	Link
EP (3)	EP1985285A3 (de)
JP (3)	JP2002541088A (de)
AT (1)	ATE442839T1 (de)
AU (1)	AU777572B2 (de)
BR (1)	BRPI0009448B8 (de)
CA (1)	CA2366787C (de)
CY (1)	CY1109641T1 (de)
DE (1)	DE60042968D1 (de)
DK (2)	DK2266537T3 (de)
ES (2)	ES2333400T3 (de)
IL (4)	IL145720A0 (de)
PT (1)	PT1169021E (de)
WO (1)	WO2000059473A1 (de)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
EP1985285A3 (de) *	1999-04-01	2009-08-12	Hana Biosciences, Inc.	Zusammensetzungen und Verfahren zur Behandlung von Lymphomen
US6723338B1 (en)	1999-04-01	2004-04-20	Inex Pharmaceuticals Corporation	Compositions and methods for treating lymphoma
US7303749B1 (en)	1999-10-01	2007-12-04	Immunogen Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
AU775373B2 (en)	1999-10-01	2004-07-29	Immunogen, Inc.	Compositions and methods for treating cancer using immunoconjugates and chemotherapeutic agents
GB0000313D0 (en)	2000-01-10	2000-03-01	Astrazeneca Uk Ltd	Formulation
US7097840B2 (en)	2000-03-16	2006-08-29	Genentech, Inc.	Methods of treatment using anti-ErbB antibody-maytansinoid conjugates
PT1389089E (pt) *	2001-03-27	2009-11-30	Phares Pharm Res Nv	Processo e composição para solubilizar um composto biologicamente activo com uma baixa solubilidade em água
CN102342938B (zh) *	2002-05-17	2014-08-20	细胞基因公司	用于治疗和控制实体瘤的方法及组合物
FR2840203B1 (fr) *	2002-05-31	2004-08-27	Scherer Technologies Inc R P	Composition pharmaceutique orale pour capsules molles contenant vinorelbine et methode de traitement
US6890558B2 (en)	2002-05-31	2005-05-10	R.P. Scherer Technologies, Inc.	Oral pharmaceutical composition for soft capsules containing vinorelbine and method of treatment
US7563810B2 (en) *	2002-11-06	2009-07-21	Celgene Corporation	Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases
RU2252764C2 (ru) *	2003-03-04	2005-05-27	Российский научный центр рентгенорадиологии МЗ РФ	Способ комплексного лечения лимфогранулематоза
US8088387B2 (en)	2003-10-10	2012-01-03	Immunogen Inc.	Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
WO2005011698A1 (en) *	2003-07-28	2005-02-10	Inex Pharmaceuticals Corporation	Combination comprising a liposome-encapsulated vinca alkaloid and a topoisomerase ii inhibitor and the use thereof for treating neoplasia
WO2006005477A1 (en) *	2004-07-09	2006-01-19	Schering Ag	Combination therapywith radiolabeled anti-cd20 antibody in the treatment of b-cell lymphoma
ATE545408T1 (de) *	2004-08-10	2012-03-15	Talon Therapeutics Inc	Zusammensetzungen und verfahren zur behandlung von leukämie
EP3050566B1 (de) *	2007-09-10	2018-11-28	Boston Biomedical, Inc.	Neue gruppe von stat3-pfad-hemmern und krebs-stammzell-pfad-hemmer
NZ602675A (en)	2008-03-18	2014-03-28	Genentech Inc	Combinations of an anti-her2 antibody-drug conjugate and chemotherapeutic agents, and methods of use
JP2012506428A (ja) *	2008-10-24	2012-03-15	グルオウセステルプハルマセウトイカルス	ガンの療法
US9801874B2 (en)	2012-11-20	2017-10-31	Spectrum Pharmaceuticals	Method for the preparation of liposome encapsulated vincristine for therapeutic use
EP2948132B1 (de) *	2013-01-24	2020-08-19	Memorial Sloan Kettering Cancer Center	Verfahren zur diagnose oder behandlung von tumoren unter verwendung sphingomyelinhaltiger liposome
EP2983790A2 (de)	2013-04-09	2016-02-17	Boston Biomedical, Inc.	Verfahren zur behandlung von krebs
TWI678213B (zh) *	2015-07-22	2019-12-01	美商史倍壯製藥公司	用於長春新鹼硫酸鹽脂質體注射之即可使用的調配物
JP7106563B2 (ja)	2016-11-29	2022-07-26	スミトモファーマオンコロジー，インコーポレイテッド	ナフトフラン誘導体、その調製、および使用方法
CA3062656A1 (en)	2017-05-17	2018-11-22	Boston Biomedical, Inc.	Methods for treating cancer
SI26542A (sl)	2023-09-12	2025-03-31	Univerza V Ljubljani	Nove liposomske formulacije in postopek za njihovo pripravo

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4217344A (en)	1976-06-23	1980-08-12	L'oreal	Compositions containing aqueous dispersions of lipid spheres
US4235871A (en)	1978-02-24	1980-11-25	Papahadjopoulos Demetrios P	Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en)	1978-03-29	1980-01-29	The United States Of America As Represented By The Secretary Of The Army	Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en)	1979-09-19	1981-04-14	Merck & Co., Inc.	Viral liposome particle
US4485054A (en)	1982-10-04	1984-11-27	Lipoderm Pharmaceuticals Limited	Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4603044A (en)	1983-01-06	1986-07-29	Technology Unlimited, Inc.	Hepatocyte Directed Vesicle delivery system
US4501728A (en)	1983-01-06	1985-02-26	Technology Unlimited, Inc.	Masking of liposomes from RES recognition
US5736155A (en)	1984-08-08	1998-04-07	The Liposome Company, Inc.	Encapsulation of antineoplastic agents in liposomes
US5077056A (en)	1984-08-08	1991-12-31	The Liposome Company, Inc.	Encapsulation of antineoplastic agents in liposomes
US4946787A (en)	1985-01-07	1990-08-07	Syntex (U.S.A.) Inc.	N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US5059421A (en)	1985-07-26	1991-10-22	The Liposome Company, Inc.	Preparation of targeted liposome systems of a defined size distribution
US4885172A (en)	1985-06-26	1989-12-05	The Liposome Company, Inc.	Composition for targeting, storing and loading of liposomes
US5171578A (en)	1985-06-26	1992-12-15	The Liposome Company, Inc.	Composition for targeting, storing and loading of liposomes
US4774085A (en)	1985-07-09	1988-09-27	501 Board of Regents, Univ. of Texas	Pharmaceutical administration systems containing a mixture of immunomodulators
US4737323A (en)	1986-02-13	1988-04-12	Liposome Technology, Inc.	Liposome extrusion method
US4837028A (en)	1986-12-24	1989-06-06	Liposome Technology, Inc.	Liposomes with enhanced circulation time
US4952408A (en) *	1988-05-23	1990-08-28	Georgetown University	Liposome-encapsulated vinca alkaloids and their use in combatting tumors
US4957773A (en)	1989-02-13	1990-09-18	Syracuse University	Deposition of boron-containing films from decaborane
WO1991017424A1 (en)	1990-05-03	1991-11-14	Vical, Inc.	Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US5165922A (en) *	1990-05-22	1992-11-24	Bristol-Myers Squibb Company	Synergistic tumor therapy with combinations of biologically active anti-tumor antibodies and chemotherapy
GB9304745D0 (en) *	1993-03-09	1993-04-28	Oncholab Ab	Use of pharmaceutical formulations
US5595756A (en) *	1993-12-22	1997-01-21	Inex Pharmaceuticals Corporation	Liposomal compositions for enhanced retention of bioactive agents
US5741516A (en) *	1994-06-20	1998-04-21	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5543152A (en) *	1994-06-20	1996-08-06	Inex Pharmaceuticals Corporation	Sphingosomes for enhanced drug delivery
US5714163A (en) *	1994-06-27	1998-02-03	Nexstar Pharmaceuticals, Inc.	Vinca alkaloid vesicles with enhanced efficacy and tumor targeting properties
US5885613A (en)	1994-09-30	1999-03-23	The University Of British Columbia	Bilayer stabilizing components and their use in forming programmable fusogenic liposomes
US5820873A (en)	1994-09-30	1998-10-13	The University Of British Columbia	Polyethylene glycol modified ceramide lipids and liposome uses thereof
US5837282A (en)	1996-10-30	1998-11-17	University Of British Columbia	Ionophore-mediated liposome loading
US6320017B1 (en)	1997-12-23	2001-11-20	Inex Pharmaceuticals Corp.	Polyamide oligomers
EP1985285A3 (de) *	1999-04-01	2009-08-12	Hana Biosciences, Inc.	Zusammensetzungen und Verfahren zur Behandlung von Lymphomen

2000
- 2000-03-31 EP EP08003804A patent/EP1985285A3/de not_active Withdrawn
- 2000-03-31 DE DE60042968T patent/DE60042968D1/de not_active Expired - Lifetime
- 2000-03-31 WO PCT/US2000/008669 patent/WO2000059473A1/en not_active Ceased
- 2000-03-31 ES ES00920004T patent/ES2333400T3/es not_active Expired - Lifetime
- 2000-03-31 DK DK10011105.3T patent/DK2266537T3/en active
- 2000-03-31 IL IL14572000A patent/IL145720A0/xx unknown
- 2000-03-31 AU AU40606/00A patent/AU777572B2/en not_active Expired
- 2000-03-31 AT AT00920004T patent/ATE442839T1/de active
- 2000-03-31 PT PT00920004T patent/PT1169021E/pt unknown
- 2000-03-31 ES ES10011105.3T patent/ES2524141T3/es not_active Expired - Lifetime
- 2000-03-31 JP JP2000609037A patent/JP2002541088A/ja active Pending
- 2000-03-31 EP EP00920004A patent/EP1169021B1/de not_active Expired - Lifetime
- 2000-03-31 BR BRPI0009448A patent/BRPI0009448B8/pt not_active IP Right Cessation
- 2000-03-31 CA CA2366787A patent/CA2366787C/en not_active Expired - Lifetime
- 2000-03-31 DK DK00920004T patent/DK1169021T3/da active
- 2000-03-31 EP EP10011105.3A patent/EP2266537B1/de not_active Expired - Lifetime
2001
- 2001-09-30 IL IL145720A patent/IL145720A/en not_active IP Right Cessation
2009
- 2009-11-17 CY CY20091101201T patent/CY1109641T1/el unknown
2011
- 2011-04-14 IL IL212390A patent/IL212390A/en not_active IP Right Cessation
- 2011-04-14 IL IL212389A patent/IL212389A/en not_active IP Right Cessation
2012
- 2012-05-01 JP JP2012104769A patent/JP5981214B2/ja not_active Expired - Lifetime
2014
- 2014-12-04 JP JP2014246221A patent/JP2015071631A/ja active Pending

Also Published As

Publication number	Publication date
EP1169021B1 (de)	2009-09-16
EP2266537A3 (de)	2012-02-22
DK2266537T3 (en)	2014-12-15
CY1109641T1 (el)	2014-08-13
BRPI0009448B1 (pt)	2018-09-11
DE60042968D1 (de)	2009-10-29
EP1985285A2 (de)	2008-10-29
ES2524141T3 (es)	2014-12-04
JP5981214B2 (ja)	2016-08-31
PT1169021E (pt)	2009-11-18
AU4060600A (en)	2000-10-23
EP2266537A2 (de)	2010-12-29
IL212389A (en)	2015-07-30
ES2333400T3 (es)	2010-02-22
ATE442839T1 (de)	2009-10-15
IL212389A0 (en)	2011-06-30
JP2012158602A (ja)	2012-08-23
CA2366787C (en)	2013-03-12
JP2015071631A (ja)	2015-04-16
WO2000059473A1 (en)	2000-10-12
BR0009448A (pt)	2002-01-08
IL145720A0 (en)	2002-07-25
EP1169021A1 (de)	2002-01-09
AU777572B2 (en)	2004-10-21
HK1152246A1 (en)	2012-02-24
EP2266537B1 (de)	2014-09-03
IL212390A0 (en)	2011-06-30
CA2366787A1 (en)	2000-10-12
EP1985285A3 (de)	2009-08-12
JP2002541088A (ja)	2002-12-03
BRPI0009448B8 (pt)	2021-05-25
IL212390A (en)	2014-08-31
IL145720A (en)	2011-05-31

Publication	Publication Date	Title
DK1169021T3 (da)	2010-01-11	Sammensætninger og fremgangsmåder til behandling af lymfom
TR200800474T2 (tr)	2008-04-21	Florfenikole aracı maddelerin hazırlanmasına ilişkin işlem.
SE8502573D0 (sv)	1985-05-23	Fluorescent lanthanide chelates useful as labels of physiologically active materials
FI965203A7 (fi)	1996-12-23	Morfiinia, polypyrrolidonia ja polyalkyleenioksidia sisältävä koostumus
TR200200068T2 (tr)	2002-05-21	Nematisital triflüorobütenler
DK1093819T3 (da)	2006-09-11	Forbindelse og præparat til tilförsel af aktive midler
TR200200205T2 (tr)	2002-06-21	MEK inhibitörleri kullanılarak kronik ağrının tedavi edilmesi
TR200103525T2 (tr)	2002-05-21	Bisiklik poliaminosit metal kompleksleri, bunları hazırlamak için yöntem ve bunların tıbbi görüntülemede kullanımı.
DK1129093T3 (da)	2003-10-20	Pyrazolopyrimidinonderivater til behandling af impotens
GB0011203D0 (en)	2000-06-28	Chemical compounds
BRPI0413785A (pt)	2006-11-07	composto, composição, e, método de tratamento de distúrbio hiperproliferativo
SE0104248D0 (sv)	2001-12-14	Method of treatment
PL338339A1 (en)	2000-10-23	Novel derivatives of tetrazole
FR2763949B1 (fr)	2000-05-12	Compose stabilisant, composition le contenant et procede l'utilisant
GB0028323D0 (en)	2001-01-03	Tetrahydrofuran-adducted group 11 -diketonate complexes as source reagents for chemical vapor depostion
EP0924970A3 (de)	2000-03-08	Reinigungslösung für elektronische Bauteile sowie Verfahren für ihre Verwendung
WO2004033423A3 (en)	2004-07-29	Anticancer compounds
HUT77933A (hu)	1998-11-30	Funkcionális terpiridin-fémkomplexek, eljárás előállításukra valamint alkalmazásuk
FI981810A0 (fi)	1998-08-24	Menetelmä alkuainepitoisuuksien määrittämiseksi
TR200001819T2 (tr)	2000-11-21	COPD tedavi yöntemi.
DK0909182T3 (da)	2002-06-10	Fremgangsmåde til fremstilling af chloriner og bakteriochloriner indeholdende polyether
TR200002755T2 (tr)	2002-05-21	Aracı hazırlamak için süreç.
WO2005039528A3 (de)	2005-06-16	Zusammensetzung zur arthrose-/arthritisbehandlung, insbesondere von gelenken
MX9801130A (es)	1998-11-29	Tiamacrolidos.
IL114646A0 (en)	1995-11-27	Method of inhibiting leukotriene biosynthesis